Advance Patient Care Through Clinical Research

Are you a rheumatologist interested in expanding treatment options for your patients? We invite you to partner with Prolato Clinical Research and learn about our active trials in lupus, Sjögren’s syndrome, systemic sclerosis, and other rheumatologic conditions.

Our goal is to streamline clinical research participation for both physicians and patients. By joining our network, you and your patients gain access to cutting‐edge therapies and the chance to contribute to medical breakthroughs in autoimmune disease management.

Why Collaborate with Us?

  1. Enhance Patient Care
    Offer your patients investigational therapies that may provide relief when standard treatments fall short. All trials include comprehensive safety monitoring and oversight.

  2. Professional Development
    Expand your practice offerings, strengthen your clinical research skill set, and connect with a community of leading rheumatology experts.

  3. Streamlined Support
    Our dedicated Business Development and Clinical Operations teams handle the heavy lifting: from regulatory paperwork to patient logistics—so you can focus on patient care.

  4. Flexible Engagement
    Collaborate at a level that suits your schedule. Refer patients to our site, become a sub‐investigator, or simply learn more about emerging therapies.

Next Steps

  1. Request a Lunch & Learn
    Fill out the brief form above or give us a call and we will work with you to pick a convenient date and time.

  2. Collaborate with Our Team
    Meet our Business Development representative and lead Coordinators, who will guide you through the trial process—from initial questions to patient enrollment and everything in between.

  3. Find Eligible Patients
    If you have patients who might benefit from these studies, our site will handle scheduling, screening, and ongoing communication with your office. They will get access to labs, treatments, and stipends.

Our Active Rheumatology Indications

  • Systemic Lupus Erythematosus (SLE)

    • Multiple Phase 2–3 trials evaluating novel biologics and oral agents

    • Options for patients with moderate to severe disease, including those on standard-of-care therapies

    • Sponsors include (among others) Sanofi, Biogen, Zenas BioPharma, and Alumis

  • Diffuse Cutaneous Systemic Sclerosis (dcSSc)

    • Phase 2 studies

    • Aimed at slowing progression of dcSSc and improving skin involvement

  • Sjögren’s Syndrome

    • Phase 2, randomized, placebo‐controlled study

    • Evaluates a novel subcutaneous therapy for adults with active Sjögren’s

Each trial has carefully defined inclusion/exclusion criteria to ensure patient safety and clear efficacy assessments. Our team can help screen and identify which patients in your practice may be eligible.